Argos Therapeutics, Inc. Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

Argos Therapeutics, Inc. Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007
5/4/2007

DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of soluble CD83 at the 7th Joint American Transplant meeting to be held in San Francisco, May 5-9. The presentations will be made in collaboration with scientists at the University of Western Ontario. “These data suggest that soluble CD83 is able to extend graft survival in transplantation, and that it can also act synergistically with other immunosuppressive agents,” commented Dr. Stephen Brand, Director of Biotherapeutics at Argos Therapeutics. “sCD83 appears to be able to maintain antigen presenting cells in an immature state, and these immunologically tolerant cells favor regulatory T-cell generation because they are less effective in activating naïve T and B cells.”

Read at BioSpace.com

• BioSpace.com

• American Society of Transplantation

• Argos Therapeutics, Inc. (Formerly Merix Bioscience)

• Clinical - Pre-Clinical

• Immune Disorder (non-specific)